Nigeria Begins Landmark Rollout of Twice-Yearly HIV Prevention Injection

​ABUJA — Nigeria has officially entered a new era of epidemic control with the rollout of Lenacapavir, a revolutionary long-acting injectable for HIV Pre-Exposure Prophylaxis (PrEP). Unlike traditional daily pills, this “game-changing” medication requires only two doses per year, offering a discreet and sustainable shield against infection.

​The Federal Government, through the National HIV, Viral Hepatitis and STDs Control Programme (NASCP), flagged off the deployment this week. Nigeria is one of only nine “early adopter” countries globally selected by the Global Fund to pilot the drug, following a recommendation by the World Health Organization (WHO) in July 2025.

​The Pilot: 8 States to Lead the Way

​The initial phase of the rollout is targeting eight priority areas based on high-risk programmatic data:

• ​North & Central: Gombe, Kwara, Benue, and the FCT.
• ​South: Anambra, Ebonyi, Akwa Ibom, and Cross River.

​Approximately 52,000 doses have been secured for this first batch. Minister of State for Health and Social Welfare, Dr. Iziaq Adekunle Salako, emphasized that this phased approach will allow the government to monitor real-world effectiveness and safety outcomes before a nationwide scale-up.

​Why Lenacapavir is Different

​Health experts are hailing the drug as a solution to “pill fatigue,” a common reason for the failure of traditional oral PrEP.

ADVERTISEMENT

• ​Adherence: Administered subcutaneously once every six months, it eliminates the need for daily reminders.

• ​Efficacy: Clinical trials (PURPOSE 1 and 2) showed near-perfect results, with some cohorts recording zero new infections among users.

• ​Privacy: The biannual schedule helps users avoid the social stigma often associated with carrying HIV-related medications.

​Important Note: Lenacapavir is a preventive tool, not a cure. It does not protect against other sexually transmitted infections (STIs) or pregnancy.

​Safety and Restrictions

​While global data suggests the drug is well-tolerated—with mild injection-site soreness being the most common side effect—the National Agency for the Control of AIDS (NACA) has issued a temporary restriction. Director-General Dr. Temitope Ilori noted that Lenacapavir is not currently recommended for pregnant women in Nigeria, citing a need for more specific clinical evidence within that demographic.

​Strategic Integration

​The introduction of Lenacapavir adds a third pillar to Nigeria’s “choice architecture” for HIV prevention, which now includes:

1. ​Daily Oral PrEP (Pills)
2. ​Cabotegravir (Two-monthly injection)
3. ​Lenacapavir (Six-monthly injection)

​By offering multiple options, health authorities aim to meet the global goal of ending AIDS as a public health threat by 2030.